Global Early-Stage Lung Cancer Diagnostics Therapy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Test Type;

EGFR test, CA test, BRAF test, ALK test, ROS1 test, HER2 test, RET test, and Others.

By End User;

Cancer research laboratories, Hospital associated laboratories, and Independent cancer diagnostic laboratories.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn135064191 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Early-Stage Lung Cancer Diagnostics Therapy Market (USD Million), 2021 - 2031

In the year 2024, the Global Early-Stage Lung Cancer Diagnostics Therapy Market was valued at USD 2286.23 million. The size of this market is expected to increase to USD 4455.21 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 10.0%.

The global early-stage lung cancer diagnostics therapy market is witnessing a transformative phase driven by advancements in diagnostic technologies and therapeutic interventions. With an increasing emphasis on early detection and personalized treatment approaches, there's a growing demand for accurate and efficient diagnostic methods to identify lung cancer at its nascent stages. Moreover, the rising prevalence of lung cancer worldwide, coupled with the pressing need for effective treatment options, has spurred significant research and development activities in this domain.

Innovations in imaging modalities, such as low-dose computed tomography (CT) scans and positron emission tomography (PET) scans, alongside advancements in molecular diagnostics and genetic testing, are revolutionizing early-stage lung cancer diagnosis. Furthermore, the evolving landscape of targeted therapies and immunotherapies is reshaping treatment paradigms, offering promising avenues for improved outcomes and enhanced survival rates among early-stage lung cancer patients. As healthcare systems worldwide focus on early intervention strategies and personalized medicine approaches, the early-stage lung cancer diagnostics therapy market is poised for substantial growth and innovation.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Test Type
    2. Market Snapshot, By End User
    3. Market Snapshot, By Region
  4. Global Early-Stage Lung Cancer Diagnostics Therapy Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Technological Advancements
        2. Increasing Awareness Programs
        3. Growing Demand for Non-invasive Diagnostics
      2. Restraints
        1. High Cost of Advanced Diagnostics
        2. Limited Access in Developing Regions
        3. Regulatory Hurdles
      3. Opportunities
        1. Personalized Medicine Approaches
        2. Emerging Markets Expansion
        3. Collaboration with Research Institutions
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Early-Stage Lung Cancer Diagnostics Therapy Market, By Test Type, 2021 - 2031 (USD Million)
      1. EGFR test
      2. CA test
      3. BRAF test
      4. ALK test
      5. ROS1 test
      6. HER2 test
      7. RET test
      8. Others
    2. Global Early-Stage Lung Cancer Diagnostics Therapy Market, By End User, 2021 - 2031 (USD Million)
      1. Cancer research laboratories
      2. Hospital associated laboratories
      3. Independent cancer diagnostic laboratories
    3. Global Early-Stage Lung Cancer Diagnostics Therapy Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Abbott Laboratories
      2. Danaher Corporation,
      3. Thermo Fischer Scientific
      4. QIAGEN N.V
      5. Illumina, Inc.
      6. Quest Diagnostics Incorporated
      7. NanoString Technologies.
      8. NeoGenomics Laboratories, In
  7. Analyst Views
  8. Future Outlook of the Market